X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Customised Blood Pressure Treatment Can Get More Protection

Content Team by Content Team
13th April 2023
in News, Research & Development
Customised Blood Pressure Treatment Can Get More Protection

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

A study from Sweden has gone on to show that patients who have been treated with drugs that are used to lower blood pressure can get better results after changing medications as compared to doubling the dosage of their existing medications. Researchers aimed at investigating if there was an optimal blood pressure drug for every individual that led to a potential treatment for blood pressure.

Notably, four varied blood pressure-lowering drugs were analysed across 280 Swedish patients for over a year. The drugs happened to be tested one after another at several different times during the study. The treatment effect varied to a significant extent for each participant. Professor of Epidemiology at Uppsala University who is also a cardiologist, Johan Sundstrom, the first author of the study, said that certain individuals achieved lower blood pressure from one medication than from another. He added that the effect of a medication change could be twice as big as the effect of doubling the dosage of the current line of drugs.

The classes of drugs for lowering the blood pressure happened to be a diuretic, a calcium channel blocker, an angiotensin receptor blocker, as well as an ACE inhibitor-

  • Lisinopril
  • Candesartan
  • Hydrochlorothiazide
  • Amlodipine

Interestingly, the study’s findings pose a challenge to the strategy that is recommended in the present treatment guidelines.

There were four blood groups that were equally favourable for all patients with high blood pressure.

It is well to note that more than two million Swedes are estimated to have high blood pressure, according to the research. That said, only a fifth of the population was found to control their blood pressure by way of drug therapy. Because of the variety of blood pressure drugs that are available on the market, patients are surely at risk of not getting the optimal drug for the first time. This can undoubtedly lead to poor blood pressure control as well as unnecessary side effects. Therefore, these personalised treatments go on to offer a potential solution.

According to Sundstrom, if they were to personalise each patient’s medication, they could indeed achieve better results and effects than if they were to choose one of the four drug groups randomly.

Notably, individualised treatment provided an extra 4.4 mm Hg in lower systolic blood pressure. Given the right drug for blood pressure, one can get better protection against future cardiovascular diseases in a faster way, said Sundstrom.

Previous Post

Elevating Vaccine Stability Through Predicting mRNA Degrades

Next Post

Research Pins Down New Target To Get Rid of Blood Cancer

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post
As Medical Uses Cope Up, Genomic Studies Reap Scale Benefits

Research Pins Down New Target To Get Rid of Blood Cancer

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In